XML 40 R30.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Information (Tables)
 9 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals
Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:
 
Quarter Ended December 31,
 
Nine Months Ended December 31,
(In millions)
2015
 
2014
 
2015
 
2014
Revenues
 
 
 
 
 
 
 
Distribution Solutions (1)
 
 
 
 
 
 
 
North America pharmaceutical distribution and services
$
39,615

 
$
37,397

 
$
119,750

 
$
106,848

International pharmaceutical distribution and services
6,022

 
6,767

 
17,726

 
20,506

Medical-Surgical distribution and services
1,568

 
1,565

 
4,579

 
4,473

Total Distribution Solutions
47,205

 
45,729

 
142,055

 
131,827

 
 
 
 
 
 
 
 
Technology Solutions - products and services
694

 
755

 
2,151

 
2,293

Total Revenues
$
47,899

 
$
46,484

 
$
144,206

 
$
134,120

 
 
 
 
 
 
 
 
Operating profit
 
 
 
 
 
 
 
Distribution Solutions (2)
$
906

 
$
803

 
$
2,742

 
$
2,333

Technology Solutions (3)
122

 
112

 
426

 
305

Total
1,028

 
915

 
3,168

 
2,638

Corporate Expenses, Net
(95
)
 
(103
)
 
(320
)
 
(317
)
Interest Expense
(87
)
 
(93
)
 
(267
)
 
(284
)
Income from Continuing Operations Before Income Taxes
$
846

 
$
719

 
$
2,581

 
$
2,037

(1)
Revenues derived from services represent less than 2% of this segment’s total revenues.
(2)
Distribution Solutions operating profit for the third quarter and first nine months of 2016 include $33 million and $215 million in pre-tax charges related to our last-in, first-out (“LIFO”) method of accounting for inventories. The third quarter and first nine months of 2015 include pre-tax LIFO charges of $95 million and $287 million. LIFO expense for the third quarter of 2016 includes a gross charge of $65 million, partially offset by a $32 million reversal of a portion of the LIFO expense recorded in the first half of 2016 due to a change in estimate. LIFO expense was less in 2016 primarily due to lower full year expectations for price increases. The third quarter and first nine months of 2016 include $17 million and $76 million of net cash proceeds representing our share of net settlements of antitrust class action lawsuits against drug manufacturers. Additionally, the first nine months of 2016 include a pre-tax gain of $52 million recognized from the sale of our ZEE Medical business.
(3)
Technology Solutions operating profit for the first nine months of 2016 includes a pre-tax gain of $51 million recognized from the sale of our nurse triage business, and for the first nine months of 2015 includes a non-cash pre-tax charge of $34 million related to the retained workforce business within our International Technology business.